Five notes from the Nov. 3 report posted by NBC affiliate KULR:
1. Total third-quarter revenue was $127.7 million, up 8.6 percent from the same period last year.
2. Exparel sales were $121.9 million, a 7.2 percent increase year over year.
3. Sales for Iovera, a preoperative cold treatment, were up 55.6 percent year over year at $4.2 million.
4. Pacira saw a GAAP net income of $17.7 million.
5. The company saw Exparel sales outpace the recovery of the nonemergency surgery market, chair and CEO David Stack said.
“This underscores the growing adoption of Exparel in outpatient settings, non-elective procedures and beyond,” he said in the report. “October saw a positive shift in market dynamics, and we expect the fourth quarter to return to more robust year-over-year top-line growth.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
